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Abstract
Background: Patients with narcolepsy-cataplexy (NC) mostly exhibit undetectable hypocretin levels. Hypocretin system is
one of the key players in the complex interaction between sleep and the cardiovascular system. We tested the hypothesis
that hypocretin deficiency affects cardiovascular risk factors by measuring nighttime and daytime ambulatory blood
pressure (BP) and the night-to-day BP ratio as well as endothelial dysfunction by the digital pulse amplitude response in
drug-free patients with NC compared to controls.
Methodology: Sleep, clinical and biological cardiovascular risk factors, fingertip peripheral arterial tonometry, and 24-hour
ambulatory BP monitoring were recorded in 50 drug-free patients with NC and 42 healthy control subjects, except for BP
monitoring available in all controls but in 36 patients with NC.
Principal Findings: More patients than controls were smokers, obese and with dyslipidemia. One-third of patients with NC
were ‘‘non-dippers’’ (defined as ,10% drop in BP during sleep) compared to only 3% of controls. The diastolic non-dipper
BP profile had up to 12-fold higher odds of being associated with NC. We noted negative correlations between mean
diastolic BP fall during night, REM sleep percentage and number of sleep onset REM periods, and a positive correlation with
mean sleep latency on the MSLT. The digital pulse amplitude response measured by fingertip was similar between NC and
controls.
Conclusion: We found a high percentage of non-dippers in patients with NC with association with REM sleep dysregulation.
The blunted sleep-related BP dip in NC may be of clinical relevance, as it may indicate increased risk for cardiovascular
events.
Citation: Dauvilliers Y, Jaussent I, Krams B, Scholz S, Lado S, et al. (2012) Non-Dipping Blood Pressure Profile in Narcolepsy with Cataplexy. PLoS ONE 7(6): e38977.
doi:10.1371/journal.pone.0038977
Editor: Yoko Hoshi, Tokyo Metropolitan Institute of Medical Science, Japan
Received March 12, 2012; Accepted May 15, 2012; Published June 29, 2012
Copyright:  2012 Dauvilliers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: This was not an industry-supported study. Prs Levy and Pepin, Drs Krams and Lado report no disclosures. Isabelle Jaussent and Sabine
Scholz report no disclosures. Prof. Dauvilliers has received speaker’s honoraria and funding for travel to conferences from UCB Pharma, Cephalon, Novartis, and
Bioprojet. Prof. Dauvilliers has participated in advisory boards of UCB and Bioprojet. This does not alter the authors’ adherence to all the PLoS ONE policies on
sharing data and materials.
* E-mail: ydauvilliers@yahoo.fr
Introduction
Narcolepsy with cataplexy (NC) is characterized by excessive
daytime sleepiness (EDS), cataplexy, and disturbed nocturnal
sleep, including parasomnias, obstructive sleep apnea syndrome,
and periodic leg movements [1]. Furthermore, frequent occur-
rences of rapid eye movement (REM) sleep onset periods during
daytime and numerous awakenings during nocturnal sleep induce
disruption of the sleep-wake cycle [1,2].
Marked decreases in hypocretin-1 in the cerebrospinal fluid and
in the number of hypocretin neurons have been demonstrated in
NC [1,3,4]. The hypocretin neurons are located exclusively in the
lateral hypothalamus, but project widely throughout the central
nervous system, including hypothalamic and brainstem structures
known to participate in central autonomic and cardiovascular
regulation [5,6].
Animal studies have explored the cardiovascular status of
hypocretin-deficient rodent during wakefulness, showing lower
arterial blood pressure (BP) compared to wild type [7,8]. More
recently, blunted NREM and REM sleep-related decreases in BP
have been shown in hypocretin-deficient mice [9]. Pharmacolog-
ical studies in mice or rats have revealed that the administration of
hypocretin stimulates arousal and elevates arterial blood pressure,
heart rate (HR), oxygen consumption, body temperature, and
plasma catecholamine levels [10–12]. The increased BP and HR
effects have been shown to be mediated mainly by sympathetic
activation [6,7,12].
Despite frequent associations between NC and obesity, type 2
diabetes mellitus, and metabolic syndrome, few studies addressing
cardiovascular consequences have been conducted in human NC
[13]. BP and HR variation and day–night BP decrease (the so-
called ‘‘dipping pattern’’) are strongly linked to the sleep-wake
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implications: a blunted nocturnal BP dip is associated with high
risk of cardiovascular morbidity and mortality [15–19]. A meta-
analysis showed that nighttime BP was a stronger predictor than
daytime BP of adverse cardiovascular events [18]. Endothelial
dysfunction is another predictive marker of cardiovascular
morbidity and mortality [20]. Reactive hyperemia peripheral
arterial tonometry (RH-PAT) is a non-invasive, operator-in-
dependent, easily reproducible technique that effectively predicts
endothelial dysfunction (an early marker for atherosclerosis) and
future adverse cardiac events [20–22].
Because hypocretin system is one of the factors involved in the
complex interaction between sleep and the cardiovascular system,
we tested the hypothesis that hypocretin deficiency may affect
markers of cardiovascular risk. We measured nighttime and
daytime ambulatory blood pressure (BP) and their night-to-day
ratio, the digital pulse amplitude response (RH-PAT) to evaluate
endothelial dysfunction in drug-free patients with narcolepsy-
cataplexy (NC) compared to controls.
Methods
Subjects
All patients and controls gave their informed written consent to
take part in the study which was approved by the Local Ethics
Committee (University Hospital, Montpellier, France). Additional
written consent was obtained from the parents of participants
under the age of 18.
Fifty patients with typical NC (30 males, 20 females; aged 14 to
76 years; median age 34 years) were examined. NC was diagnosed
according to the revised International Classification of Sleep
Disorders [23], including the presence of EDS, clear-cut and
frequent cataplexy, and HLA DQB1*0602 positivity. A lumbar
puncture was performed in 17 patients to measure CSF
hypocretin-1, and low levels (,110 pg/ml) [4] were systematically
found. All participants underwent a standardized face-to-face
clinical interview to determine age at NC onset, duration of
disease, Epworth sleepiness score, and frequency of cataplexy. All
patients were drug-free for NC at the time of evaluation: 33 were
drug-naive and 17 were treated with psychostimulants (modafinil,
n=15; methylphenidate, n=2), including 3 with anticataplectics
(venlafaxine, n=1; clomipramine, n=2) and 2 with gamma-
hydroxybutyrate. All treatments were suspended at least two weeks
before the study.
Forty-two community-dwelling healthy control participants (16
males, 26 females; aged 20 to 53 years; median age 31.5 years)
were recruited from local associative networks (Montpellier,
France).
No patients or controls had any psychiatric disorder, based on
DSM-IV TR criteria, and none was taking any medication known
to influence sleep at the time of the study. Regarding the presence
of medication influencing cardiovascular function, five subjects
(four patients with NC and one control) were treated with an
antihypertensive drug, two patients with a drug for diabetes, and
one patient with a treatment for hyperlipidemia.
Clinical and Biological Cardiovascular Risk Factors
All participants underwent a routine medical history and
physical examination, and body-mass index (BMI) and waist and
hip circumference were measured. All participants fasted for
venous blood sampling between 7 and 8 AM, with similar
procedures to assess for cardiovascular biological risk factors.
Presence of baseline cardiovascular risk factors was defined as
follows: (1) hypertension as a conventional BP of at least 130 mm
Hg systolic and 85 mm Hg diastolic, or as use of antihyperten-
sive drugs; (2) diabetes mellitus as positive patient history,
a fasting blood glucose concentration of at least 7.0 mmol/L, or
use of antidiabetic drugs; (3) hyperlipidaemia as total serum
cholesterol .240 mg/dL, triglyceride $150 mg/L, or treatment
with lipid-lowering drugs; (4) metabolic syndrome diagnosed
according to National Cholesterol Education Program Adult
Treatment Panel III criteria [24]; (5) insulin resistance defined as
the homeostasis model assessment (HOMA) [25], (6) personal
history of coronary artery disease (CAD) or stroke; (7) history of
CAD or stroke in first-degree relatives; (8) smoking history; and
(9) alcohol intake.
Polysomnographic Recordings
All patients (n=50) and 23 controls underwent one night of
polysomnography (PSG) recording in the sleep laboratory
followed by the Multiple Sleep Latency Test (MSLT) the next
day. Sleep recording included 3 EEG leads (C3, C4, and O2), 2
electroculograms, one chin electromyogram, and an electrocar-
diogram. Airflow was measured using a nasal cannula and
mouth thermocouple, thoracoabdominal movement by respira-
tory belts (piezoelectric), and arterial oxygen saturation by finger
pulse oximetry. Sleep recordings were manually scored by
standard criteria for sleep stages as well as microarousals and
respiratory events [26]. Obstructive sleep apneas were defined
as complete cessation of airflow for .10 sec associated with
thoracoabdominal movements, and hypopneas were defined as
a $50% reduction in airflow plus a $3% drop in SpO2 and/
or a microarousal. Indices of periodic leg movements (PLM)
were calculated as PLMW (awake), PLMS (asleep), PLMS in
REM and NREM sleep, and PLM-MAs (microarousal-associat-
ed) [27].
Digital Pulse Amplitude
Digital pulse amplitude was measured between 7 and 8 AM
after overnight fasting in all participants in supine position by RH-
PAT using an Endo-PAT finger sensor (Itamar Medical Ltd,
Caesarea, Israel) [21,22]. Pulse amplitude was recorded electron-
ically in both fingers and analyzed by a computerized automated
algorithm to obtain average pulse amplitude for 30-second
intervals from forearm cuff deflation up to 4 minutes. The RH-
PAT index, a measure of endothelial dysfunction, was calculated
as the natural logarithm of the average amplitude of the PAT
signal after 90- to 120-second deflation divided by the average
amplitude of the PAT signal during the 210 seconds prior to cuff
inflation.
24-h Ambulatory Blood Pressure Monitoring
Twenty-four-hour ambulatory blood pressure monitoring
(ABPM) was done on the non-dominant arm using a validated
automatic oscillometer (i-MAPAH, Eutherapie) following the PSG-
MSLT recording in 36 patients and in all controls (n=42). All
participants were instructed to continue their usual daily activities
but without napping. BP and HR readings were automatically
recorded at 15-minute intervals in daytime and 60-minute
intervals at night. Daytime and nighttime were individually
predetermined depending on the participants’ usual awake and
sleep schedule. Recordings were analyzed to obtain average 24-
hour daytime and nighttime systolic and diastolic BP and HR.
Systolic and diastolic BP were used to assess dipping. A ‘‘non-
dipping BP profile’’ was defined as a nocturnal BP dip,10% lower
than daytime BP [19].
Non-Dipping Blood Pressure in Narcolepsy
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Categorial variables for the sample are presented as percent-
ages, and quantitative variables as medians with ranges. Distribu-
tions were mostly skewed, according to Shapiro-Wilk’s test. Chi
square or Fisher’s exact tests were run to compare categorical
variables between the two groups, and the Mann-Whitney test for
continuous variables (table 1 and table 2). Spearman’s rank order
correlations were applied to determine associations between two
continuous variables. Univariate comparisons between patients
with NC and controls were made using logistic regression analysis
and quantified using odds ratios (OR) and 95% confidence
intervals (CI) for exposure variables (pulse amplitude measures by
RH-PAT and 24-hour ambulatory blood pressure). ORs evaluated
the strength of the associations between exposure variables and the
two groups (controls and patients). More precisely, OR is the risk
of being narcoleptic when the subject is exposed. For the blood
pressure example, OR means that for 1 variable unit (1 mmHg)
increase, the risk of being narcoleptic is OR value. ORs were
further adjusted for clinical and biological variables associated with
narcolepsy (at p,0.10) in table 1 which could be potential
confounders (excluding dislypidemia due to the low proportion of
dyslipidemia in the sample and table’s cells have expected counts
less than 5) using multivariate logistic regression models (table 3
and table 4). To identify factors associated with a low PAT ratio
for the 90–120-second intervals, continuous variables were divided
into two groups according to low or high PAT ratio using a 1.49
threshold (first tertile of the distribution). To obtain a sufficient
statistical power, we decided to adjust the two groups for potential
confounders instead of performing analysis on homogeneous sub-
groups of patients or controls. The latter choice may be considered
as particularly difficult as narcolepsy with cataplexy is an orphan
disease associated with several comorbid conditions such as
obesity. Similar procedures were applied for factors associated
with a non-dipping vs. dipping BP profile, with significance at
p,0.05. Statistical analyses were performed using SAS, version
9.2 (SAS Institute, Cary, NC, USA).
Results
Clinical and Biological Characteristics
Table 1 presents the clinical and biological characteristics of
patients and controls, revealing a larger proportion of men with
NC. More patients than controls were currently smokers (50.0%
vs. 19.1%, p=0.002), obese (27.6% vs. 0%, p,0.0001) and with
dyslipidemia (12% vs 0, p=0.03). Other clinical and biological
variables did not differ significantly between groups (Table 1).
Based on case and control differences for gender, smoking, and
BMI, all between-group results were further adjusted accordingly.
Two patients with NC had a personal history of CAD, with none
for controls.
Sleep Parameters
As expected, Table 2 depicts that patients with NC had
significantly shorter sleep and REM sleep latency, longer wake
time after sleep onset, greater percentages of N1 and REM sleep,
and lower N2 and N3 sleep. Between-group comparison showed
a higher AHI index, and PLMS index with and without micro-
arousals in NC, with no significant difference for PLMW, mean
nocturnal O2 saturation, or desaturation index. Only 6.4% of
patients with NC had AHI .30 per hour, without any in the
controls. MSLT results revealed shorter mean sleep latency in NC
with a higher number of sleep onset REM periods (SOREMPS)
(Table 2). No controls had abnormal mean sleep latency (,8
minutes), and only one control had one SOREMP.
Endothelial Function
Regardless of the distribution (continuous or categorical), RH-
PAT 90–120 measurements were not significantly lower in the NC
group than in controls, before and after adjusting for gender,
smoking, and BMI (OR=0.76 95% CI=0.43–1.33, OR=0.78
95% CI=0.41–1.51, respectively) (Table 3). RH-PAT of the
whole population divided into tertiles revealed a 1.49 cut-off for
the first tertile, without any difference between the percentage of
patients and controls below this threshold. Comparing patients
with NC with a low amplitude response to those with a larger
response (Log RH-PAT 90–120 s ,0.4, n=19 vs .0.4, n=31),
we failed to report any difference with gender, age, BMI, clinical
and biological data, and sleep variables (Table 3). As previous
psychostimulant intake may have affected the endothelial function,
additional analyses were performed but the results remained
similar between drug-naive, drug-free patients for at least 15 days,
and controls.
24-hour Ambulatory Systolic and Diastolic BP
Patients with NC showed lower daytime diastolic BP and HR
than controls, with similar tendency for the mean daytime pressure
(Table 4). Large between-group differences were noted for
diastolic and mean pressure dips (i.e. .10% drop in BP during
sleep): lower in NC, with a similar tendency for systolic dips.
Figure 1 shows a higher percentage of diastolic non-dippers in
patients with NC compared to controls (30.56% vs 2.94%,
p=0.002). When the non-dipping night-to-day ratio was below
15% (instead of 10%), results also showed a higher percentage of
diastolic non-dippers in NC compared to controls (63.89% vs.
32.35%, p=0.0086, OR=5.12 95% CI [1.51–17.30] after
adjusting for gender, smoking, and BMI). We further analyzed
factors associated with the diastolic dip (,10% drop during sleep)
in patients with NC. Hence, the diastolic non-dipper status was
associated with dyslipidemia (22.3% in non-dipper vs 0% in
dipper, p=0.02), with a similar tendency for REM sleep
percentage (27.1% vs 22.2%, p=0.08). No other between-dipper
group differences were found for gender, age, disease duration,
BMI, clinical and biological data, and other sleep variables
(including sleep efficiency, total sleep time, sleep stage %, mean
PLMS and AHI indexes, and number of O2 desaturations). As
previous psychostimulant intake may have affected BP, additional
analyses were performed but results remained unchanged between
drug-naive, drug-free patients for at least 15 days, and controls.
We noted in the whole population a negative correlation
between mean diastolic dip and REM sleep percentage (r=20.46,
p,0.0003) and number of SOREMPs (r=20.44, P=0.001), and
a positive correlation with mean sleep latency on the MSLT
(r=0.49, P=0.0002). No association was found between RH-
PAT, and mean 24-h blood pressure or dipper status.
Discussion
For the first time, 24-hour ambulatory blood pressure (BP)
monitoring and the peripheral endothelial function were reported
in a large group of drug-free NC patients in comparison to
controls. Although the digital pulse amplitude response, measured
by reactive hyperemia-peripheral artery tonometry (RH-PAT),
was substantially similar between NC and controls, one-third of
NC patients were non-dippers vs. only 3% of controls. Non-dipper
diastolic BP status was strongly associated with NC by an up to 12-
fold higher odds ratio, with significant associations with nocturnal
and diurnal REM sleep, and objective daytime sleepiness.
Patients with NC showed lower daytime diastolic BP, and HR
than controls. This could be partially explained by lesser physical
Non-Dipping Blood Pressure in Narcolepsy
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literature reports that mean sleeping BP and the 24-h BP pattern
(dipping vs. non-dipping) are more reliable indicators than
daytime BP, and better predictors of cardiac morbidity and
mortality risks [15–19]. We found a nighttime non-dipping
diastolic BP pattern in NC, with 31% of patients failing to show
the 10% physiological sleep-related decline, and 64% failing to
show the 15% fall point. Although systolic dip was also lower in
Table 1. Clinical and biological characteristics of patients with narcolepsy-cataplexy (n=50) and controls (n=42).
Controls N=42 Narcoleptics N=50
Variable n % n % p
(d)
Gender
Male 16 38.10 30 60.00 0.04
Female 26 61.90 20 40.00
Age (median [range]) 31.50 [20.00–53.00] 34.00 [14.00–76.00] 0.73
Waist/hip ratio
,1 35 100.00 43 91.49 0.13
$1 0 0.00 4 8.51
Body mass index (kg/m
2) 21.40 [18.30–29.10] 25.11 [17.01–38.30] ,0.0001
Waist circumference, cm
#102 in men or #88 in women 31 86.11 37 78.72 0.39
.102 in men or .88 in women 5 13.89 10 21.28
Smoker
No 34 80.95 25 50.00 0.002
Yes 8 19.05 25 50.00
Alcohol intake
No 21 52.50 26 53.06 0.62
Occasional 15 37.50 15 30.61
Frequent
(a) 4 10.00 8 16.33
Family history of CAD
(b)
No 37 92.50 40 86.96 0.49
Yes 3 7.50 6 13.04
Diabetes mellitus
No 42 100.00 48 96.00 0.50
Yes 0 0.00 2 4.00
Hypertension
No 41 97.62 46 92.00 0.37
Yes 1 2.38 4 8.00
Dyslipidemia
No 42 100.00 44 88.00 0.03
Yes 0 0.00 6 12.00
Metabolic syndrome
No 39 100.00 43 91.49 0.12
Yes 0 0.00 4 8.51
HOMA-IR
(c)
#2.5 37 94.87 44 97.78 0.59
.2.5 2 5.13 1 2.22
C-reactive protein (mg/L)
#0.5 14 37.84 14 31.11 0.43
[0.5–2.0] 14 37.84 14 31.11
.2.0 9 24.32 17 37.78
(a)Frequent intake was defined as at least daily ingestion;
(b)CAD: coronary artery disease.
(c)HOMA-IR: homeostasis model assessment (HOMA), IR: insulin resistance.
(d)p-values from Chi-square test or Fisher’s exact test or Mann-Whitney test.
doi:10.1371/journal.pone.0038977.t001
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found for non-systolic dipper status. Our ambulatory BP
monitoring had some limitations, performing every 15 minutes
during the day but every 60 minutes at night to preserve sleep
Table 2. Polysomnography and multiple sleep latency tests in patients with narcolepsy-cataplexy (n=50) and in controls (n=23).
Controls N=23 Narcoleptics N=50 p
(e)
Median [Range] Median [Range]
Total sleep time 417.00 [289.00–474.00] 418.50 [275.00–539.00] 0.37
Sleep efficiency 87.35 [58.93–95.39] 86.05 [57.69–96.52] 0.29
N1(%) 3.49 [0.47–14.65] 9.25 [1.67–38.40] ,0.001
N2 (%) 55.40 [29.66–68.67] 47.60 [17.86–60.91] 0.001
N3 (%) 20.96 [7.20–44.56] 18.81 [7.51–39.49] 0.02
REM sleep (%) 16.60 [9.44–27.40] 23.71 [10.80–37.00] ,0.001
REM sleep latency 85.00 [61.00–206.00] 9.50 [0.00–274.00] ,0.001
Sleep latency 15.00 [2.00–84.00] 4.00 [0.00–18.00] ,0.001
WASO
(a) 37.00 [11.00–120.00] 68.00 [15.00–189.00] 0.003
AHI
(b) 1.50 [0.00–9.20] 4.10 [0.00–44.21] 0.02
PLMW index
(c) 2.96 [0.00–102.22] 5.68 [0.00–48.57] 0.24
PLMS index 0.00 [0.00–7.91] 2.10 [0.00–103.84] 0.003
PLMS-MA 0.00 [0.00–1.24] 0.29 [0.00–8.23] 0.01
Microarousal index 12.31 [4.19–27.10] 14.10 [0.00–47.96] 0.42
Mean SaO2 96.00 [88.00–98.00] 96.00 [92.00–98.00] 0.85
SaO2 less than 90% duration 0.02 [0.00–46.57] 0.01 [0.00–6.41] 0.51
O2 desaturation index 2.16 [0.00–36.33] 3.20 [0.00–51.56] 0.63
Mean sleep latency, min 17.31 [8.60–20.00] 5.40 [0.40–16.80] ,0.001
SOREMPs
(d), n 0.00 [0.00–1.00] 4.00 [0.00–5.00] ,0.001
Data are expressed as medians [Min-Max].
(a)WASO: Wake time after sleep onset;
(b)AHI: Apnea hypopnea index;
(c)PLM: periodic leg movements (PLMS: in sleep; PLMW: in wake time; PLMS-MA: with microarousals);
(d)SOREMPs: Sleep Onset REM Periods;
(e)p-values from Mann-Whitney test.
doi:10.1371/journal.pone.0038977.t002
Table 3. Pulse amplitude measures by reactive hyperemia with finger plethysmography (reactive hyperemia peripheral arterial
tonometry – RH-PAT) in patients with narcolepsy-cataplexy (n=50) compared to controls (n=42).
Controls Narcoleptics





Median [range] 1.83 [0.82–3.52] 1.73 [0.88–3.70] 0.76 [0.43–1.33]
(c) 0.33 0.78 [0.41–1.51]
(c) 0.46
Log RH- PAT 90–120 measures 0.65 (0.39) 0.58 (0.36) 0.62 [0.20–1.87]
(c) 0.39 0.71 [0.20–2.58]
(c) 0.60
Mean (SD) 0.65 (0.39) 0.58 (0.36) 0.62 [0.20–1.87]
(c) 0.39 0.71 [0.20–2.58]
(c) 0.60
Log RH-PAT 90–120 measures
,0.4 (n, %) 13 30.95 19 38.00 1 0.48 1 0.76
$0.4 (n, %) 29 69.05 31 62.00 0.73 [0.31–1.74] 0.85 [0.31–2.35]
RH-PAT 90–120 measures
#1.49 (n, %) 13 30.95 17 34.00 1 0.71 1 0.88
[1.49–2.22] (n, %) 13 30.95 18 36.00 1.06 [0.38–2.92] 1.05 [0.33–3.38]
.2.22 (n, %) 16 38.10 15 30.00 0.72 [0.26–1.97] 0.79 [0.24–2.57]
(a)RH-PAT: reactive hyperemia peripheral arterial tonometry.
(b)Adjusted for gender, smoking, BMI.
(c)OR for 1-unit increase; OR means that for 1 variable unit increase, the risk of being narcoleptic was OR value.
doi:10.1371/journal.pone.0038977.t003
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ambulatory monitoring, all participants were instructed to
continue their usual daily activities but without napping; however
we do not have objective information on the sleep/wake pattern
during BP recording.
We recently reported lower cardiac activation associated with
periodic leg movements during sleep (PLMS) in NC, probably due
to changes in baroreflex sensitivity [29]. Both lower PLMS-related
HR response and the absence of or reduction in the nocturnal dip
may be considered highly sensitive predictors of cardiovascular
morbidity and mortality [15–19,30–31]. However, based on
discrepancies between the general non-dipper profile and the
one of NC with low daytime diastolic BP and HR without any
increased of hypertension, we may also further hypothesize the
absence of higher cardiovascular risk in NC.
One strength of this study is the between-group comparison of
robust cardiovascular markers in drug-free patients with NC by
considering during meaning time potential clinical and biological
Table 4. 24-hour ambulatory blood pressure monitoring of patients with narcolepsy-cataplexy (n=36) and of controls (n=42).
Controls N=42 Narcoleptics N=36 OR [95% CI]
(b) p OR [95% CI]
(b,c) p
(c)
Median [Range] Median [Range]
Ambulatory blood pressure (mmHg)
24-h systolic 112.00 [98.00–132.00] 115.50 [97.00–165.00] 1.03 [0.99–1.09] 0.17 0.99 [0.93;1.05] 0.73
24-h diastolic 72.50 [61.00–85.00] 70.50 [49.00–113.00] 0.99 [0.94–1.05] 0.72 0.94 [0.88;1.01] 0.07
Daytime systolic 116.50 [101.00–139.00] 120.50 [99.00–168.00] 1.03 [0.98–1.07] 0.23 0.98 [0.93;1.04] 0.51
Daytime diastolic 76.00 [66.00–87.00] 73.00 [52.00–115.00] 1.03 [0.98–1.07] 0.23 0.98 [0.93;1.04] 0.51
Mean daytime pressure
(a) 90.00 [79.33–100.33] 90.00 [69.33–132.67] 0.99 [0.94–1.04] 0.69 0.93 [0.87;0.99] 0.03
Daytime heart rate (/min) 77.00 [57.00–97.00] 70.00 [56.00–89.00] 1.00 [0.95–1.06] 0.93 0.94 [0.88;1.00] 0.06
Nighttime systolic 102.00 [69.00–122.00] 107.00 [93.00–155.00] 1.05 [1.00–1.10] 0.05 1.02 [0.97;1.08] 0.40
Nighttime diastolic 61.00 [47.00–76.00] 63.50 [46.00–109.00] 1.05 [0.98–1.11] 0.15 1.01 [0.94;1.08] 0.88
Mean nighttime pressure 75.00 [62.33–90.00] 77.67 [63.00–124.33] 1.05 [0.99–1.12] 0.10 1.01 [0.94;1.08] 0.77
Nighttime heart rate (/min) 61.50 [50.00–83.00] 61.00 [46.00–79.00] 0.97 [0.92–1.03] 0.35 0.99 [0.93;1.05] 0.70
Systolic dip 12.36 [–6.00–22.10] 10.63 [22.10–23.13] 0.94 [0.87–1.02] 0.15 0.92 [0.84;1.01] 0.08
Diastolic dip 17.60 [25.40–31.70] 13.15 [21.80–26.40] 0.90 [0.83–0.97] 0.006 0.87 [0.79;0.96] 0.006
Mean pressure dip 13.67 [26.00–29.00] 11.67 [21.00–23.00] 0.90 [0.83–0.98] 0.02 0.86 [0.77;0.96] 0.01
(a)(PAS-2*PAD)/3).
(b)OR for 1-unit increase; OR means that for 1 variable unit (1 mmHg) increase, the risk of being narcoleptic was OR value.
(c)Adjusted for gender, smoking, BMI.
doi:10.1371/journal.pone.0038977.t004
Figure 1. Non-dipping diastolic BP profile in patients with narcolepsy-cataplexy (n=36) and in controls (n=42). Diastolic non-dippers
(defined as a nocturnal diastolic BP dip,10% lower than daytime BP) were significantly higher in patients with narcolepsy-cataplexy compared to
controls (30.56% vs 2.94%, p=0.002).
doi:10.1371/journal.pone.0038977.g001
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and with dyslipidemia than controls but without any difference for
hypertension, diabetes mellitus, metabolic syndrome, insulin
resistance, and personal history of coronary artery disease or
stroke. We found associations between diastolic non-dipper status
and dyslipidemia in NC with a similar tendency for REM sleep
percentage [15,16,19]. Importantly, we found negative correla-
tions between mean diastolic dip, REM sleep percentage, and
number of SOREMPs, and a positive correlation with mean
daytime sleep latency. Our findings suggest that the abnormal
night-to-day cardiovascular regulation found in NC is sleep
related, being impacted by both REM sleep and hypersomnia,
hallmarks of narcolepsy-cataplexy. Unlike NREM sleep, REM
sleep has been associated with marked sympathetic activation and
with BP and HR instability [32]. Moreover, vasoconstriction in
active skeletal muscles during REM sleep, depending on
sympathetic outflow, is required to prevent drops in systemic
arterial pressure [33]. A blunted sleep-related decrease in BP was
reported in animal models of narcolepsy leading to prominent
sleep-related increases in BP during REM sleep [9]. Recent data
also suggest that patients with NC displayed a nighttime nondip-
ping BP pattern with increased of systolic BP during nighttime
REM sleep [34]. Altogether these results suggest a decreased
night-to-day BP pattern in human NC, attributable to a potentially
clinically significant hypocretin deficiency.
A reliable, non-invasive method using a PAT sensor was
developed to detect vascular changes in patients at high
cardiovascular risk [20–22]. Recent population-based studies
further confirmed that the PAT ratio independently predicts
cardiovascular events, and early detection facilitates therapy and
prognosis [20–22]. In our study, the endothelium-dependent
vasodilatation response was similar between NC and controls,
suggesting normal arterial smooth muscle cell functioning. We
failed to report any determinant of endothelial function results in
NC. These results may contradict previous studies on PAT in sleep
disorders especially in sleep apnea syndrome [35], however only
few patients (6.4%) with NC had AHI above 30, allowing for
potential type II errors. Overall, our RH-PAT results suggest
a preserved vasomotor microvessel function in NC that may be
related to low daytime BP findings.
Unlike a recent study [36], we found no association between
RH-PAT results, mean 24-h blood pressure, and dipper status in
either patients or controls, possibly because most participants had
normal diurnal BP at baseline (94.6%). Literature reports that
significant percentage of patients with NC are obese, exhibit type
II diabetes or metabolic syndrome [1,13], and are taking life-long
treatments with psychostimulants, known to affect the autonomic
nervous and cardiovascular systems [1]. Altogether these results
may indicate an increased risk for cardiovascular events in NC but
the low daytime diastolic BP and HR without any associated
hypertension found in the present study may also attenuate this
potential risk. Given the lack of relevant data regarding
cardiovascular co-morbidities and mortality in the literature,
long-term prospective observational cohorts should be examined
to assess these issues including measurements of endothelial
dysfunction and 24-hour-BP.
In conclusion, we demonstrated a large percentage of diastolic
non-dippers in patients with NC compared to controls, with
associations with REM sleep regulation. The blunted sleep-related
BP dip in NC may be of clinical relevance as it may indicate
increased risk for cardiovascular events.
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